Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03039114 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03039114 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 26 participants.
The verdict
NCT03039114, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of parsaclisib when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).
Interventions
- DRUG Parsaclisib
- DRUG Hexal
- DRUG Gazyvaro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03039114
The ClinicalTrials.gov registry entry for NCT03039114 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Parsaclisib is the first listed.
NCT03039114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03039114 about?
NCT03039114 is a clinical study titled "Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)". The purpose of this study is to evaluate the safety and efficacy of parsaclisib when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).
What is the current status of trial NCT03039114?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-02-15. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT03039114?
The interventions under investigation include: Parsaclisib (DRUG), Hexal (DRUG), Gazyvaro (DRUG).
Who is sponsoring clinical trial NCT03039114?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.